UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
Amendment No. 1
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR
THE QUARTERLY PERIOD ENDED MARCH 31, 2020
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR
THE TRANSITION PERIOD FROM ________TO ________
Commission File Number: 000-54554
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Nevada
|
|
45-1226465
|
(State
or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
4093 Oceanside Boulevard, Suite B
Oceanside, California 92056
(Address of principal executive offices, including zip code)
(760) 295-7208
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes [X] No [
]
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large Accelerated
Filer
|
[
]
|
|
Non-Accelerated
Filer
|
[X]
|
Accelerated Filer
|
[
]
|
|
Smaller reporting
company
|
[X]
|
|
|
|
Emerging growth
company
|
[
]
|
Indicate by check
mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes [ ] No [X]
As of July 6, 2020, the Registrant had 1,947,438,492 outstanding
shares of Common Stock with a par value of $0.001 per share.
1
Explanatory Note
The
sole purpose of this Amendment No. 1 to the Quarterly Report on
Form 10-Q (the “Form 10-Q”) of Therapeutic Solutions International,
Inc. for the quarterly period ended March 31, 2020, filed with the
Securities and Exchange Commission on July 6, 2020, is to furnish
Exhibit 101 to the Form 10-Q in accordance with Rule 405 of
Regulation S-T. Exhibit 101 to the Form 10-Q provides the
consolidated financial statements and related notes from the Form
10-Q formatted in XBRL (eXtensible Business Reporting
Language).
No
other changes have been made to the Form 10-Q. This Amendment
No. 1 to the Form 10-Q speaks as of the original filing date of the
Form 10-Q, does not reflect events that may have occurred
subsequent to the original filing date, and does not modify or
update in any way disclosures made in the original Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files
on Exhibit 101 hereto are deemed not filed or part of a
registration statement or prospectus for purposes of Sections 11 or
12 of the Securities Act of 1933, as amended, are deemed not filed
for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, and otherwise are not subject to liability under those
sections.
2
PART II - OTHER INFORMATION
Item 6.
Exhibits
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
31.1
|
|
Rule
13a-14(a)/Section 302 Certification of Principal Executive
Officer
|
31.2
|
|
Rule
13a-14(a)/Section 302 Certification of Principal Financial
Officer
|
32.1
|
|
Certification pursuant to 18 U.S.C. Section 1350/Rule 13a-14(b)
|
101
|
|
XBRL
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
THERAPEUTIC SOLUTIONS
INTERNATIONAL, INC.
Date: July 9,
2020
|
By: /s/ Timothy G.
Dixon
|
|
|
Timothy G. Dixon
|
|
|
President and Chief
Executive Officer
(Principal Executive
Officer)
|
|
3